Topical lincosamide antibiotic. Doctors prescribe it for inflammatory acne, often combined with benzoyl peroxide to prevent resistance.
Topical application
AProven efficacy. Two or more independent RCTs with instrumental endpoints.
Clindamycin monotherapy increases antibiotic resistance risk. AAD and EADV guidelines recommend it only in combination with benzoyl peroxide or a retinoid.
Clindamycin Phosphate is a topical antibiotic of the lincosamide class. A prodrug: the phosphate ester is inactive, and skin keratinocyte phosphatase hydrolyzes it to active clindamycin. In Spanish pharmacies it is prescription-only: Dalacin T (Pfizer) 1%, Zindaclin 1% gel, Dalacin C 1% lotion. Where applied. Mild-to-moderate inflammatory acne (papulopustular form). Concentration 1% in gel, lotion, solution, cream. Applied 1-2 times daily to affected areas. Course 8-12 weeks. Mechanism. Binds the 50S subunit of the Cutibacterium acnes (Propionibacterium acnes) bacterial ribosome, suppresses protein synthesis. Bacteriostatic effect. Additionally suppresses neutrophil chemotaxis to the inflammation focus – an anti-inflammatory effect independent of the antimicrobial one. Evidence base. AAD 2024 and Spanish AEDV 2023 recommend topical clindamycin as part of combination therapy for mild-moderate acne. Monotherapy efficacy is moderate: 40-60% inflammatory-lesion reduction in 12 weeks (Leyden 2007). Combined with 5% benzoyl peroxide (BPO) efficacy rises to 70-80% with reduced resistance risk (which is critical). Resistance controversy. Since the 2000s C. acnes resistance to clindamycin has been rising – already 30-50% of strains in Europe. AAD 2024 and AEDV 2023 ban clindamycin monotherapy – only in combination with BPO, azelaic acid, or retinoids (adapalene, tretinoin). Course duration – no more than 12 weeks. Safety. Skin systemic absorption is 5-10%. Locally: erythema, peeling, burning in the first 2 weeks in 5-15% of patients. Serious adverse effect – pseudomembranous colitis (C. difficile) – described in isolated cases with topical use, on predisposing background. Pregnancy and lactation – FDA category B. Topical clindamycin is allowed in pregnancy and lactation at standard concentrations. Acceptable in the 2nd-3rd trimesters. Do not apply to the nipple during breastfeeding – the infant may ingest. Therapy monitoring. At 8-12 weeks reassess effect with a dermatologist. Without improvement – switch to oral isotretinoin (severe acne), azelaic acid (mild alternative), benzoyl peroxide + retinoid. Not suitable for long-term, multi-year use due to resistance risk.
Irritation potential
LowAllergen risk
LowThe Evigrade extension adds an evidence panel to Wildberries, Goldapple, Letu, iHerb, Sephora and 12 more stores. This ingredient and every other one in the product show evidence-tier, allergen risk and pregnancy/lactation flags at a glance.
Clindamycin Phosphate should be used with caution during pregnancy. Consulting a dermatologist or OB-GYN is advisable.
Topical lincosamide antibiotic.
The INCI name is Clindamycin Phosphate.
Published: · updated:
Pregnancy
Caution